Humana Inc. HUM

UnitedHealth (UNH) stock trades at 22.5 times its past year's adjusted earnings, which are normalized net income with stock-based pay added back. That multiple leaves little room for error after three years of shrinking operating margins, sitting near the stock's 10-year median despite fundamentally weaker profitability. But the price looks different against the profit expected for fiscal 2026 and fiscal 2027. So what are UnitedHealth investors betting on.

What a time it’s been for Humana. In the past six months alone, the company’s stock price has increased by a massive 136%, reaching $391.06 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.

UnitedHealth shareholders spent five years waiting for a stock that barely budged, yet something inside the company kept growing the whole time. Whether that something is enough to make UNH worth holding now depends on costs that management has not yet fully tamed.

Humana (HUM) moved sharply higher this week after Barclays shifted its rating on the insurer to Overweight from Equalweight, indicating that the shares could outperform sector peers. At around US$397.93, Humana’s recent 4.63% 1 day share price return and 3.21% 30 day share price return build on a strong year to date share price return of 50.46%. However, the 3 year total shareholder return has declined 15.34%, suggesting the latest upgrade is being read as a fresh shift in sentiment rather...

Shares of health insurance company Humana (NYSE:HUM) jumped 8% in the afternoon session after Barclays upgraded the stock from Equalweight to Overweight.

Barclays upgraded Humana stock to Overweight from Neutral and raised its price target to $515 from $407.

Healthcare stocks rose late Friday afternoon with the NYSE Healthcare Index increasing 0.3% and the

Investing.com -- Humana Inc. (NYSE:HUM) shares rose 6% Friday after Barclays upgraded the health insurer to overweight from equal-weight ahead of the upcoming Medicare Star ratings release.

Barclays just broke its silence on Humana with a conviction call that sent shares surging well past anything the broader health care sector is doing today, raising the question of whether this upgrade signals the start of something bigger or a rally built on a single opinion.

If you own CVS Health (CVS), the primary focus shifts from 2026 execution toward potential headwind variables heading into 2027. Management raised its 2026 earnings outlook on its fiscal Q2 2026 call in August. It also gave an early read on 2027, a quarter sooner than usual. One warning in that read came with no number. Over the past three months, the shares lost 15.2%, while the S&P 500 gained 5.0%. What is the 2027 problem CVS would not put a number on.

By Exec Edge Editorial Staff Health insurance premiums have climbed for years. Deductibles have climbed right along with them. Yet a growing number of American households are choosing neither, opting instead for a decades-old alternative, which is not health insurance, built around monthly contributions and community values. “People are clearly paying high premiums now,” Liberty […] The post Liberty HealthShare’s Dorsey Morrow Makes the Financial Case for Healthsharing on Becker’s Healthcare Pod

UnitedHealth Group (UNH) stock has risen about 40% since late March 2026, against close to 19% for the S&P 500. Read cold, that looks like a recovery nobody could have timed. It was not hidden. The company had said plainly, months before the shares turned, that it would give up members to rebuild margin.

Toronto, Ontario--(Newsfile Corp. - September 23, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (OTCQB: TMPTF) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce it has entered into a distribution agreement dated August 25, 2026 (the "Distribution Agreement") with CenterWell Pharmacy, Inc. ("CenterWell") the pharmacy services brand of Humana Inc, a major U.S. health...

UnitedHealth (UNH) has turned its profits around. Operating earnings rose 55% in the second quarter of 2026, and management raised its full-year adjusted earnings guide to $19.50 to $20 a share. Revenue, though, has nearly stopped growing. So the rest of the recovery rests on something the company only partly controls: the medical bills of the people it insures.